|[June 18, 2014]
Trevena CEO to Present at the 9th Annual JMP Securities Healthcare Conference
KING OF PRUSSIA, Pa. --(Business Wire)--
Trevena, Inc. (NASDAQ:TRVN), a clinical stage biopharmaceutical company
focused on the discovery and development of G protein coupled receptor
(GPCR) biased ligands, today announced that Maxine Gowen, Ph.D., its
president and chief executive officer, will present at the 9th Annual
JMP Securities (News - Alert) Healthcare Conference on Wednesday, June 25, 2014 at
11:00 a.m. EDT at The Westin Grand Central in New York City.
To access a live audio webcast of the presentation, please visit the
"Investors" section at www.trevenainc.com.
The webcast will be archived for 30 days.
Trevena, Inc. is a clinical stage biopharmaceutical company that
discovers, develops and intends to commercialize therapeutics that use a
novel approach to target G protein coupled receptors, or GPCRs. Using
its proprietary product platform, Trevena has identified and advanced
three differentiated biased ligand product candidates into the clinic -
TRV027 to treat acute heart failure, TRV130 to treat moderate-to-severe
acute pain intravenously, and TRV734 to treat moderate-to-severe acute
and chronic pain orally. Trevena also is advancing additional product
candidates in its portfolio, including a preclinical program focused on
central nervous system indications.
[ Back To TMCnet.com's Homepage ]